Skip to main content

Table 3 Characteristics of patients

From: Recombinant human soluble thrombomodulin improves mortality in patients with sepsis especially for severe coagulopathy: a retrospective study

Ā 

Mild coagulopathy

(nā€‰=ā€‰37)

Severe coagulopathy

(nā€‰=ā€‰32)

P value

Male, n (%)

25 (67.6)

23 (71.9)

0.796

Age (years)

69 [38ā€“94]

72.5 [33ā€“91]

0.110

Shock, n (%)

14 (42.4)

13 (40.6)

1.000

AKI, n (%)

15 (42.9)

18 (56.3)

0.332

APACHE II score

26.6ā€‰Ā±ā€‰8.1

29.8ā€‰Ā±ā€‰10.8

0.229

SOFA score

6.2ā€‰Ā±ā€‰3.5

7.5ā€‰Ā±ā€‰2.5

0.114

ISTH overt DIC score

3.4ā€‰Ā±ā€‰0.7

5.3ā€‰Ā±ā€‰0.6

<ā€‰ 0.001

Mechanical ventilation, n (%)

31 (88.6)

30 (93.8)

0.675

Renal replacement therapy, n (%)

25 (71.4)

22 (68.8)

1.000

Vasopressor use, n (%)

24 (68.6)

24 (75.0)

0.598

Lactate (mmol/L)

32.0ā€‰Ā±ā€‰22.8

38.3ā€‰Ā±ā€‰21.5

0.289

Time for normalize lactate level (h)

94.8ā€‰Ā±ā€‰142.6

88.3ā€‰Ā±ā€‰87.0

0.854

Cancer, n (%)

6 (16.7)

5 (15.6)

1.000

rhTM dose (mg/kg)

0.041ā€‰Ā±ā€‰0.018

0.048ā€‰Ā±ā€‰0.023

0.218

Duration of rhTM

administration (days)

5.4ā€‰Ā±ā€‰1.8

6.3ā€‰Ā±ā€‰3.5

0.181

Coagulation tests

ā€ƒProthrombin time ratio

1.34ā€‰Ā±ā€‰0.28

1.42ā€‰Ā±ā€‰0.26

0.212

ā€ƒAntithrombin III activity (%)

57.7ā€‰Ā±ā€‰20.6

54.5ā€‰Ā±ā€‰21.8

0.581

ā€ƒD-dimer (103Ā ng/ml)

14.0ā€‰Ā±ā€‰15.4

40.0ā€‰Ā±ā€‰65.0

<ā€‰ 0.001

ā€ƒPlatelet count (103/Ī¼l)

10.0ā€‰Ā±ā€‰10.1

5.3ā€‰Ā±ā€‰3.2

0.004

ā€ƒFibrinogen (mg/dl)

420.3ā€‰Ā±ā€‰216.7

410.0ā€‰Ā±ā€‰117.7

0.813

  1. Collected data are when rhTM administration start
  2. Data are presented as meanā€‰Ā±ā€‰standard deviation unless otherwise stated. DIC: disseminated intravascular coagulation, AKI: acute kidney injury, APACHE II: acute physiologic and chronic health evaluation, SOFA: sequential organ failure assessment, ISTH: International Society on Thrombosis and Haemostasis, rhTM: recombinant human soluble thrombomodulin